ArQule's badly battered shares managed a quick surge this morning on news that the biotech's lead drug tivantinib scored a positive outcome in a Phase II metastatic prostate cancer study.
Late last week investors wound up using Intercept Pharmaceuticals as a punching bag after new data on its NASH drug for fatty liver disease raised some troubling questions about its safety and efficacy. Its stock was hit hard, forced down 30% in hours as analysts mulled the implications of potential trouble.
Johnson & Johnson CEO Alex Gorsky likes to hint at trouble developing its Chinese sales, but don't expect him to come right out and criticize the prickly Chinese government. In an brief interview with The Wall Street Journal, Gorsky said J&J was looking for new acquisitions in China, with new drugs for lung cancer as one of its topic targets.
Two years after Michael Yeadon and a close-knit group of Pfizer investigators managed to grab some of the pharma giant's anti-inflammatory assets on the way out the door at Sandwich, they've drummed up a $33 million B round for their biotech from some U.S. and European investors. And now they're set to launch a midstage clinical program to help determine the value of what they took with them when launching Ziarco.
Sage Therapeutics has successfully resolved a rare seizure disorder among the majority of patients in its small but closely watched Phase I/II study, adding more promising outcomes to the early evidence that helped inspire one of this year's most successful biotech IPOs. In the data update out Monday morning investigators say the 73% overall response rate in their study is also being mirrored among a small group of patients who are receiving the drug on an emergency-use basis.
After sending out signals that it might be running into trouble with a short-duration study of a new triple combination drug for its hepatitis C regimen, Merck investigators hailed the clear success of an 8-week test but confirmed analysts' fears in a batch of 4-week data released at the meeting of the American Association for the Study of Liver Diseases.
New Haven, CT's Trevi Therapeutics banked another $11 million in venture cash, bringing its B round to $26 million and giving it the cash it needs to complete a pivotal trial for its top prospect.
INC Research is the latest among Big Pharma's biggest contractors to pull off an IPO, raising $150 million and joining its largest rivals on Wall Street.
Avanir Pharmaceuticals, awaiting FDA approval for a new migraine treatment, got a letter from the agency pointing out flaws in submitted data, a regulatory hiccup that could derail the company's plans.
After crunching the data on Intercept's clinical study of OCA for nonalcoholic steatohepatitis, investigators say they tracked some distinct improvements for patients suffering from the liver disease. But they also fretted about some troubling safety issues as well as inadequate efficacy endpoints that will have to be carefully considered in follow-up studies, tempering some of the high excitement that has been stoked by some analysts and the biotech's investors ahead of a pivotal Phase III study.
A group of FDA advisers voted in favor of approving Rockwell Medical's iron-replacement treatment for dialysis patients, setting aside concerns about the drug's pivotal data and burnishing the company's hopes of finally launching its top prospect.
In this week's EuroBiotech Report, after a brief post-AbbVie deal lull in discussion of Shire's tax rate, the Irish-headquartered drugmaker found its financial structures in the headlines once again when The Guardian made it the centerpiece of an investigation into the role Luxembourg plays in global tax schemes.
Novartis' new multiple myeloma is treatment too risky to be approved, a group of FDA advisers voted, dealing a blow to the drugmaker and its hopes of launching the cancer drug next year.
Gene therapy startup Spark Therapeutics has picked up the FDA's coveted breakthrough-therapy designation for its lead candidate, a one-time treatment that promises a permanent solution some rare eye diseases.
GlaxoSmithKline made a high-profile decision to exit the cancer drug field in its recent deal with Novartis, but as Reuters reports, a band of specialists inside GSK still has ambitious plans for developing next-gen therapies.
Allergan today confirmed what much of the industry has been buzzing about for some time now: It's in takeover discussions with another company other than the acquisition-hungry Valeant. And the business news outlets quickly identified Actavis as the interested party.
Tolero Pharmaceuticals has pocketed a second tranche of its Series B funding round, netting $22.4 million in total as it prepares to take its expirimental marrow cancer treatment into late-stage development.
The FDA has rejected Aeterna Zentaris' orphan treatment, taking serious issues with its pivotal data and further battering the foundering biotech's share price.
Four months after Bind Therapeutics lost marquee development partner Amgen, Merck has stepped up to take the Big Biotech's place in the lineup. The pharma giant, which has been investing heavily in its cancer drug pipeline, is turning over a pair of early-stage drug candidates to see if Bind's delivery technology can amp up their efficacy.